BioDiscovery

The companies will develop an assay and software package for Thermo's cancer research product portfolio.

The deal covers BioDiscovery's products, including the NxClinical 4.0 software system for genomic variant analysis and interpretation.

The companies will join their respective technologies to offer customers a single solution for next-generation sequencing data interpretation.

The software allows researchers to visualize copy number variation, absence of heterozygosity, and single nucleotide variations.

The deal provides customers a complete end-to-end solution for cytogenomic array and next-generation sequencing services, the firms said.

NEW YORK (GenomeWeb) –Life science software firm BioDiscovery this week unveiled NXClinical, a new addition to its product portfolio that's tailored specifically for the clinical laboratory market and provides tools for analyzing, processing, and reporting the results of genetic tests.

NEW YORK (GenomeWeb) – Genomic analysis software maker BioDiscovery said today it will use a $157,000 grant from the National Cancer Institute to analyze and improve copy number variant data from The Cancer Genome Atlas program.

Innopsys has launched its newest microarray scanner, the InnoScan 910 microarray scanner. The two-color fluorescence scanner is capable of reading high-density microarrays with a resolution of 1 micron per pixel.

NantHealth said this week that it has launched a fully integrated genomic and transcriptomic analytic engine that can identify mutations such as copy number variants and genomic rearrangements in DNA, RNA, and protein pathways accurately and efficiently.

NEW YORK (GenomeWeb News) – BioDiscovery and N-of-One today announced a marketing agreement to provide genomic analysis interpretation solutions.

Pages

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.